Skip to main content
[Preprint]. 2024 May 2:rs.3.rs-4237867. [Version 1] doi: 10.21203/rs.3.rs-4237867/v1

Figure 1: CDK4/6i Retrial Cohorts:

Figure 1:

A flow/CONSORT diagram outlining how patients were divided into cohorts for data analysis is shown here. From our 195 total patients, patients were first separated depending upon why their first CDK4/6i regimen was discontinued. Patients who discontinued therapy due to toxicity were considered Cohort 1. The remaining patients (who had stopped initial CDK4/6i due to progression of disease (POD)) were further separated depending upon what type of combination regimen was chosen on retrial. Cohort 2 represented patients who kept the same CDK4/6i but changed endocrine therapy (ET) partner. Cohort 3 represented patients who were treated with a different CDK4/6i. Of note, 14 patients were treated with 3 separate lines of therapy containing a CDK4/6i and therefore were documented as separate treatment instances (treatments 1 and 2 vs treatments 2 and 3). These individual patients ended up in multiple cohorts to account for their multiple treatment instances.